Targeted radionuclide therapy
Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases
... Targeted radionuclide therapy (TRT) allows precise delivery of systemically administered radioactivity to disseminated cancer ...non-radiolabeled targeted therapies, which only affect cells ...
12
A random walk approach to estimate the confinement of α-particle emitters in nanoparticles for targeted radionuclide therapy
... in targeted radionuclide therapy justify all the efforts to develop in vivo α -particle nanogenerators and to enable a wider application of 230 U, 225 Ac, 224 Ra and 223 ...the radionuclide is ...
26
Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review
... TRT: targeted radionuclide therapy; ECT: emission computed tomography; Ho-166-PLLA-MS: Ho-166 labeled poly (L-lactic acid) microsphere; RE: radio-embolization; SIRT: selective internal radiation ...
15
Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy
... Multiplexed immunofluorescence (IF) was performed by sequentially staining 4-µm-thick formalin-fixed, paraffin-embedded whole tissue sections with standard, primary mAbs paired with a unique fluorochrome, followed by ...
13
Developmental trends in targeted radionuclide therapy of neuroendocrine tumors
... Survival and response after peptide receptor radionuclide therapy with [ 90 Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl[r] ...
6
Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy
... of targeted therapies against intrinsic melanoma properties, such as the presence of melanins, offered another window for those patients without therapy ...
10
Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody
... For targeted radiotherapy using long-lived radioisotopes, the intense kidney retention becomes a major dosimetric concern in terms of renal tissue toxicity and often limits its ...
13
PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues
... corresponding to the amount that was injected in the therapy studies (0.3 or 3.0 nmol, respectively) affected the uptake into receptor-expressing tissues. The amount of 0.3 nmol was selected to approximate the ...
12
Nuclear Model Calculations on the Production of Auger Emitter 165Er for Targeted Radionuclide Therapy
... cancer therapy offer the opportunity to deliver a high radiation dose to the tumor cells with high radiotoxicity while minimizing toxicity to normal tissue ...
9
<p><sup>131</sup>I-labeled polyethylenimine-entrapped gold nanoparticles for targeted tumor SPECT/CT imaging and radionuclide therapy</p>
... I enabled BmK CT-Au PENPs- 131 I to be used for tumor-targeted radionuclide therapy were evaluated in tumor-bearing nude mice in this study. No signi fi cant differences were observed among the ...
15
Integrin Targeted Delivery of Radiotherapeutics
... for targeted radionuclide therapy of tumors, the PEGylated A20FMDV2 tracers may have limitations due to the low tumor uptake values (less than 3 ...
10
In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies
... tumor-targeted radionuclide therapy of PCa. PSMA-targeted agents labeled with the β-emitting radioisotope 177 Lu are currently evaluated ...
14
Cancer biomarkers for targeted therapy
... Tumor-associated antigens (TAA) or cancer biomarkers are major targets for cancer therapies. Antibody- based agents targeting cancer biomarkers include monoclonal antibodies (MoAbs), radiolabeled MoAbs, bispecific T cell ...
7
Mesothelin as a biomarker for targeted therapy
... Despite the fact that there are few clinical trials of MSLN-targeted vaccines and the results of these tri- als have been disappointing, many preclinical studies are still ongoing. One study showed that a ...
18
Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs)
... receptor radionuclide ther- apy (PRRT) with radiolabeled somatostatin analogs was introduced as promising treatment modality for patients with inoperable or metastasized ...
11
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
... In recent years, PRRT with either 177Lu-Dotatate or 90Y- Dotatoc has been shown to be highly effective and seldom toxic in progressive GI-NETs, generally obtaining results largely comparable with competitive therapies, ...
7
Radiation-Induced Second Cancer Risk Estimates From Radionuclide Therapy
... of radionuclide therapy in the clinical setting is expected to increase significantly over the next ...five radionuclide therapy patients was ...
5
Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
... of individualized PRRT with safe administration of higher activities (data not published), possibly resulting in improved outcomes. This study has various limitations. It is retrospective and comprises a very limited ...
8
<p>Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights</p>
... grade 2 panNETs. CAPTEM when compared to single-agent TEM improved progression-free survival (PFS) 22.7 months (mo) vs 14.4 mo (p=0.023), overall survival (OS) not reached vs 38 mo (p=0.012), and overall response rate ...
11
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
... Knowledge • Cancer biology: it is fundamental in translational oncology to understand and integrate the wealth of already- existing molecular oncology information, which in part was generated by translational oncology ...
96